Alemtuzumab in previously treated CLL
Study . | Treatment and regimen . | No. patients . | Patients refractory to fludarabine, % . | OR, % . | CR, % . | OR, % refractory . |
|---|---|---|---|---|---|---|
| Osterborg et al (1997)47 | Alemtuzumab 30 mg, 3× weekly intravenously, up to 12 w | 29 | — | 42 | 4 | — |
| Kennedy et al (2001)48 | Alemtuzumab 30 mg, 3× weekly intravenously until maximum response | 77 | 99 | 44 | 25 | 44 |
| Rai et al (2002)49 | Alemtuzumab 30 mg, 3× weekly intravenously, up to 16 w | 24 | 71* | 33 | 0 | 29 |
| Keating et al (2002)50 | Alemtuzumab 30 mg, 3× weekly intravenously, up to 12 w | 93 | 48* | 33 | 2 | 29 |
| Stilgenbauer et al (2004)51 | Alemtuzumab 30 mg, 3× weekly subcutaneously, up to 12 w | 50 | 100 | 36 | 2 | 36 |
| Cortelezzi et al (2005)52 | Alemtuzumab 10 mg, 3× weekly subcutaneously, up to 18 w | 16 | 88 | 50 | 25 | 50 |
| Moreton et al (2005)53 | Alemtuzumab 30 mg, 3× weekly intravenously until maximum response | 91 | 48* | 55 | 36 | 50 |
| Kennedy et al (2002)54 | Alemtuzumab 30 mg, 3× weekly intravenously; fludarabine 25 mg/m2, 3× monthly until maximum response | 6 | 100 | 83 | 16 | 83 |
| Nabhan et al (2004)55 | Alemtuzumab 3-30 mg, 3× weekly intravenously, up to 4 w; rituximab 375 mg/m2 weekly intravenously, up to 4 w | 12 | 100 | 8 | 0 | 8 |
| Faderl et al (2003)56 | Alemtuzumab 30 mg, 2× weekly intravenously, up to 4 w; rituximab 375 mg/m2 weekly intravenously, up to 4 w | 48† | 54 | 52 | 8 | — |
| Wierda et al (2004)57 | Cyclophosphamide 250 mg/m2 days 3-5 intravenously; fludarabine 25 mg/m2 days 3-5 intravenously; alemtuzumab 30 mg/m2 days 1, 3, 5 intravenously; rituximab 375-500 mg/m2 day 2, (monthly, 6 cycles) | 17 | 59 | 52 | 14 | — |
| Osuji et al (2005)58 | Alemtuzumab 30 mg, 3× weekly intravenously until maximum response | 24 | 62 | 54 | 18 | — |
Study . | Treatment and regimen . | No. patients . | Patients refractory to fludarabine, % . | OR, % . | CR, % . | OR, % refractory . |
|---|---|---|---|---|---|---|
| Osterborg et al (1997)47 | Alemtuzumab 30 mg, 3× weekly intravenously, up to 12 w | 29 | — | 42 | 4 | — |
| Kennedy et al (2001)48 | Alemtuzumab 30 mg, 3× weekly intravenously until maximum response | 77 | 99 | 44 | 25 | 44 |
| Rai et al (2002)49 | Alemtuzumab 30 mg, 3× weekly intravenously, up to 16 w | 24 | 71* | 33 | 0 | 29 |
| Keating et al (2002)50 | Alemtuzumab 30 mg, 3× weekly intravenously, up to 12 w | 93 | 48* | 33 | 2 | 29 |
| Stilgenbauer et al (2004)51 | Alemtuzumab 30 mg, 3× weekly subcutaneously, up to 12 w | 50 | 100 | 36 | 2 | 36 |
| Cortelezzi et al (2005)52 | Alemtuzumab 10 mg, 3× weekly subcutaneously, up to 18 w | 16 | 88 | 50 | 25 | 50 |
| Moreton et al (2005)53 | Alemtuzumab 30 mg, 3× weekly intravenously until maximum response | 91 | 48* | 55 | 36 | 50 |
| Kennedy et al (2002)54 | Alemtuzumab 30 mg, 3× weekly intravenously; fludarabine 25 mg/m2, 3× monthly until maximum response | 6 | 100 | 83 | 16 | 83 |
| Nabhan et al (2004)55 | Alemtuzumab 3-30 mg, 3× weekly intravenously, up to 4 w; rituximab 375 mg/m2 weekly intravenously, up to 4 w | 12 | 100 | 8 | 0 | 8 |
| Faderl et al (2003)56 | Alemtuzumab 30 mg, 2× weekly intravenously, up to 4 w; rituximab 375 mg/m2 weekly intravenously, up to 4 w | 48† | 54 | 52 | 8 | — |
| Wierda et al (2004)57 | Cyclophosphamide 250 mg/m2 days 3-5 intravenously; fludarabine 25 mg/m2 days 3-5 intravenously; alemtuzumab 30 mg/m2 days 1, 3, 5 intravenously; rituximab 375-500 mg/m2 day 2, (monthly, 6 cycles) | 17 | 59 | 52 | 14 | — |
| Osuji et al (2005)58 | Alemtuzumab 30 mg, 3× weekly intravenously until maximum response | 24 | 62 | 54 | 18 | — |
OR indicates overall response; —, not reported.
Definition of refractoriness to fludarabine: no CR or PR with such a treatment or progression within the 6 months from last course. These two series (Rai et al49 and Keating et al50 ) share some patients
Includes patients with CLL/prolymphocytic leukemia (PLL), PLL, and mantle-cell lymphoma (MCL)